India Globalization Capital Inc
$ 0.34
-0.74%
24 Apr - close price
- Market Cap 33,314,000 USD
- Current Price $ 0.34
- High / Low $ 0.35 / 0.33
- Stock P/E N/A
- Book Value 0.09
- EPS -0.06
- Next Earning Report 2026-06-15
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.83 %
- 52 Week High 0.50
- 52 Week Low 0.24
About
India Globalization Capital, Inc. buys and resells physical infrastructure commodities. The company is headquartered in Potomac, Maryland.
Analyst Target Price
$4.12
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-17 | 2025-08-05 | 2025-06-30 | 2025-02-12 | 2024-11-07 | 2024-08-07 | 2024-06-24 | 2024-02-14 | 2023-11-09 | 2023-08-10 | 2023-06-30 |
| Reported EPS | -0.02 | -0.02 | -0.0148 | -0.02 | -0.02 | -0.02 | -0.03 | -0.4 | -0.09 | -0.05 | -0.04 | -0.0759 |
| Estimated EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 | -0.05 | 0 | None |
| Surprise | 0 | 0 | 0.0152 | 0 | 0.01 | 0.01 | 0 | -0.36 | -0.05 | 0 | -0.04 | 0 |
| Surprise Percentage | 0% | 0% | 50.6667% | 0% | 33.3333% | 33.3333% | 0% | -900% | -125% | 0% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-06-15 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.025 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IGC
2026-04-23 05:10:18
IGC Pharma has added Kerwin Medical Center in Dallas, Texas, as a clinical site for its Phase 2 CALMA trial, which is evaluating IGC-AD1 for agitation in Alzheimer's disease. The company has reported approximately 80% enrollment and is nearing completion, with the addition of Kerwin Medical Center aiming to strengthen site quality, expand patient access, and enhance clinical rigor. Dr. Alka Khera, a behavioral neurologist, will serve as the Principal Investigator, bringing specialized expertise to the trial.
2026-04-22 22:10:18
This article lists ETFs that invest in IGC Pharma, Inc. stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, and price performance. The primary ETF mentioned is AdvisorShares Psychedelics ETF (PSIL), which holds 0.39% of its assets in IGC Pharma, Inc. The purpose is to make investing in such stocks more accessible with lower risk through diversified funds.
2026-04-22 12:40:17
IGC Pharma has added Kerwin Medical Center in Dallas, Texas, as a clinical site for its Phase 2 CALMA trial, which is evaluating IGC-AD1 for agitation in Alzheimer's disease. The company announced approximately 80% enrollment completion for the trial and anticipates the new site will provide essential behavioral neurology expertise and expand patient access to support final recruitment and data quality. The addition of Kerwin Medical Center is expected to accelerate the trial towards full enrollment and completion.
2026-04-20 20:10:16
IGC Pharma has received authorization in Colombia to synthesize, formulate, and conduct development activities with psilocybin, positioning the company to explore its potential in neuropsychiatric symptoms associated with dementia. This authorization allows IGC Pharma to evaluate new therapeutic approaches in areas like depression and anxiety, complementing their ongoing Phase 2 CALMA trial for agitation in Alzheimer's disease. The company views this as a capital-efficient way to expand its focus on the broader challenges of Alzheimer's.
2026-04-20 20:10:15
IGC Pharma has secured new funding through two high-interest promissory notes totaling $584,960 from FirstFire Global Opportunities Fund and Vanquish Funding Group, to be used for general working capital. These notes carry a 12% interest rate and are convertible into common stock at a 25% discount to the lowest trading price if an Event of Default occurs. The agreements introduce new debt and potential dilution risk for shareholders in adverse scenarios, though conversion is capped at 19.99% without shareholder approval.
2026-04-20 20:10:15
IGC Pharma has secured $514,000 in promissory note financings from FirstFire Global Opportunities Fund and Vanquish Funding Group to bolster its working capital. These 12% notes, maturing in April and March 2027 respectively, include original issue discounts and provisions for conversion under specific conditions related to an event of default and shareholder approval.
